ARTEMIDE-Lung03: A phase 3, randomized, double-blind, multicenter, global study of rilvegostomig or pembrolizumab in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic non-squamous non-small-cell lung cancer whose tumors express PD-L1.

Authors: Clarissa Mathias, Yasushi Goto, Carolin Gross-Ophoff-Mueller, Shun Lu, Delvys Rodriguez-Abreu, Alona Zer, Moritz Wolfgang Drachsler, Maozhen Gong, James Hurlock, Jakub Tyszecki, Byoung Chul Cho

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8653

Source: Full article

---

Abstract

TPS8653